The Cough Company Is Now Alitair Pharmaceuticals, Inc.
MORRISTOWN, New Jersey – December 15, 2011 – Alitair Pharmaceuticals, Inc., an early stage pharmaceutical company with multiple therapeutic candidates in development, today announced that The Cough Company is now doing business under the Alitair name. Information about Alitair’s prescription cough product strategy can be found on
the new Alitair corporate website, www.alitair.com.
"This name change reflects a broadening of our strategy beyond the cough market," said Alitair President and CEO, William W. Howard, Ph.D. "With recent favorable preliminary results in the lab for our prescription drug overdose reduction platform delivery technology and two new product candidates, we now have therapeutic candidates for the treatment of cough, asthma, and COPD in addition to our prescription drug overdose reduction/abuse deterrence technology. With plans to serve a far broader patient population, The Cough Company name was too limiting."
The new Alitair website provides in-depth information about Alitair Pharmaceuticals, the Alitair management team, the prescription cough market, and an overview of the prescription drug overdose problem. It also features an easy-to-use Contact Us section where visitors can send messages to Alitair requesting more information.
"We are actively seeking development partners and funding to further develop our products and technology," said William W. Howard, Ph.D., "and our new corporate website is designed to address the preliminary information needs of prospective partners and investors."
About Alitair Pharmaceuticals:
Alitair Pharmaceuticals, Inc. is focused on developing technologies and medicines to address serious medical conditions and societal problems. The Company has a twin focus on respiratory therapeutics and drug safety. Alitair discovers, invents, and develops medicines for the treatment of respiratory illnesses. The Company is also developing a drug delivery technology designed to reduce prescription drug overdose and deter drug abuse. Alitair has out-licensed two prescription cough candidates that use a proprietary ion-exchange resin technology developed by Alitair, and other therapeutic candidates are available for out-licensing. Additional information about Alitair is available on the Alitair website at www.alitair.com.
Source: Alitair Pharmaceuticals, Inc.
Contact: Faith Pomeroy-Ward
Vice President, Corporate Development